NextCure, Inc. (NXTC)
5.33
+0.21
(+4.10%)
USD |
NASDAQ |
Nov 06, 16:00
5.54
+0.21
(+3.94%)
After-Hours: 20:00
NextCure Enterprise Value : 5.887M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 5.887M |
| November 05, 2026 | 5.032M |
| November 04, 2026 | 8.003M |
| November 03, 2026 | 8.247M |
| November 02, 2026 | 7.372M |
| October 30, 2026 | 9.874M |
| October 29, 2026 | 10.75M |
| October 28, 2026 | 9.996M |
| October 27, 2026 | 7.453M |
| October 26, 2026 | 5.460M |
| October 23, 2026 | 4.463M |
| October 22, 2026 | 3.405M |
| October 21, 2026 | 6.233M |
| October 20, 2026 | 6.334M |
| October 19, 2026 | 7.270M |
| October 16, 2026 | 9.590M |
| October 15, 2026 | 12.19M |
| October 14, 2026 | 10.97M |
| October 13, 2026 | 9.752M |
| October 12, 2026 | 11.22M |
| October 09, 2026 | 13.41M |
| October 08, 2026 | 11.79M |
| October 07, 2026 | 10.89M |
| October 06, 2026 | 7.331M |
| October 05, 2026 | 4.747M |
| Date | Value |
|---|---|
| October 02, 2026 | 4.910M |
| October 01, 2026 | 4.381M |
| September 30, 2026 | 4.585M |
| September 29, 2026 | 3.913M |
| September 28, 2026 | 4.870M |
| September 25, 2026 | 4.870M |
| September 24, 2026 | 5.683M |
| September 23, 2026 | 3.812M |
| September 22, 2026 | 5.276M |
| September 21, 2026 | 6.416M |
| September 18, 2026 | 9.101M |
| September 17, 2026 | 7.270M |
| September 16, 2026 | 8.735M |
| September 15, 2026 | 10.12M |
| September 14, 2026 | 11.22M |
| September 11, 2026 | 12.68M |
| September 10, 2026 | 13.94M |
| September 09, 2026 | 17.04M |
| September 08, 2026 | 18.46M |
| September 04, 2026 | 16.02M |
| September 03, 2026 | 16.10M |
| September 02, 2026 | 14.11M |
| September 01, 2026 | 11.87M |
| August 31, 2026 | 10.20M |
| August 28, 2026 | 8.979M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.983B |
| Oncolytics Biotech, Inc. | 51.10M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.085B |
| Anixa Biosciences, Inc. | 94.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.89M |
| Total Expenses (Quarterly) | 14.89M |
| EPS Diluted (Quarterly) | -2.805 |
| Earnings Yield | -198.7% |
| Normalized Earnings Yield | -186.10 |